The effects of recombinant human growth hormone therapy on thyroid function in pediatric patients with growth hormone deficiency.

ABSTRACT:

Background

Recombinant human growth hormone (rhGH) was approved for the therapy of pediatric patients with growth hormone deficiency (GHD) by the Food and Drug Administration (FDA) of the United States in 1985. This study aims to evaluate the effects of rhGH therapy on thyroid function in pediatric patients with GHD.

Methods

A total of 55 pediatric patients, who had been diagnosed with GHD and received rhGH therapy for 6-24 months, and who could regularly come to our hospital for outpatient visits from May 1, 2014 to April 30, 2017, were selected for the study. All of the patients were treated for at least six months, among which 44 patients were treated for 12 months, and 32 patients were treated for 18 months, and 16 patients were treated for 24 months.

Results

(I)

SUBMITTER: Yao Q 

PROVIDER: S-EPMC8107847 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature